Ligand in licensing deal with TG Thera for IRAK-4 inhibitor program

24 June 2014

US drugmaker Ligand Pharmaceuticals (Nasdaq: LGND) has signed an exclusive global license accord with TG Therapeutics (Nasdaq: TGTX) for the development and commercialization of Ligand’s interleukin-1 receptor associated kinase-4 (IRAK-4) inhibitors.

The IRAK-4 program is in preclinical development for potential use in certain cancers and autoimmune diseases. The deal follows last month’s announcement of a collaboration with AstraZeneca for development of products to treat dyslipidemia, including hypertriglyceridemia using Ligand’s LTP TECHNOLOGY.

Ligand has also out-licensed rights to five programs to Viking Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK